Found 4333 with Last Name = 'bo' and Initial = 'y' 
Affinity DataKi: 0nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compou...More data for this Ligand-Target Pair
Affinity DataKi: 0nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compou...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0300nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0730nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.130nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP3 subtype(Homo sapiens (Human))
Merck Frosst Centre For Therapeutic Research
Curated by PDSP Ki Database
Merck Frosst Centre For Therapeutic Research
Curated by PDSP Ki Database
Affinity DataKi: 0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.180nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.180nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.190nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.190nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.190nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.190nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.200nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.200nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.200nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.210nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.210nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.210nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.210nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.220nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.220nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.220nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.230nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.230nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.230nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.240nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Affinity DataKi: 0.25nMAssay Description:Inhibition of human CAH7 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.260nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compou...More data for this Ligand-Target Pair
